Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Chronic-Phase 7Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Breast Neoplasms 5Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Accelerated Phase 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Blast Crisis 3Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Mycosis Fungoides 2

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Dasatinib × Clear all
NCT01092728 2016-09-05

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

M.D. Anderson Cancer Center

Phase 2 Terminated
19 enrolled 7 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡